GoAI
Get started
EC Healthcare logo

EC Healthcare

2138.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.425

−HK$0.01 · -2.30%

Aug 24, 1:46 PM HKT

2138.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

EC Healthcare, an investment holding firm, delivers an extensive range of medical and healthcare services throughout Hong Kong, Macau, and mainland China. Its operations are structured into three primary divisions: Medical, Aesthetic Medical and Beauty and Wellness, and an 'Others' category. The company's diverse service offerings include quasi-medical treatments, beauty and wellness programs, medical imaging, surgical procedures, aesthetic medicine, dentistry, hair restoration, vaccinations, chiropractic care, psychological support, and orthopedic services. Beyond direct patient care, EC Healthcare also provides administrative and management support, laboratory diagnostics, various marketing and performance marketing solutions, and even travel agency services. Furthermore, it retails beauty and skincare products, manages healthcare machinery, engages in property investment, offers multi-channel networking, and extends its expertise to veterinary services. Its product and service portfolio is primarily marketed under proprietary brands such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. Established in 2005 and headquartered in Mong Kok, Hong Kong, the company was formerly known as Union Medical Healthcare Limited before rebranding to EC Healthcare in April 2021.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
HK
CEO
Lyn Wade Lu
Listed since
Mar 11, 2016
Employees
2,400

Market position

Day range

Current HK$0.425

52-week range

Current HK$0.425

Open
HK$0.41
Previous close
HK$0.435
Volume
542K
1.52× average
Average volume
355.92K
Average daily volume
Market cap
499.48M HKD
Beta
1.03
Market reference 1
50-day average
HK$0.3887
+9.34% above average
200-day average
HK$0.5006
-15.10% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.04B HKD
P/E (TTM)
-1.25×
P/B (TTM)
0.36×
P/S (TTM)
0.13×
EV / EBITDA
1.9×
Earnings yield
-73.87%
Free cash flow yield
111.26%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
22.85%
Operating margin
7.85%
Net margin
-10.68%
Return on equity
-29.08%
Return on assets
-9.26%
Return on invested capital
1.03%

Financial health

Debt / equity
0.91×
Current ratio
0.91×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends98%58%19%-21%Gross margin, FY2022: 88.03%Gross margin, FY2023: 85.73%Gross margin, FY2024: 84.18%Gross margin, FY2025: 80.73%Gross margin, FY2026: 15.92%Operating margin, FY2022: 12.44%Operating margin, FY2023: 5.65%Operating margin, FY2024: 2.59%Operating margin, FY2025: 2.29%Operating margin, FY2026: 0.92%Net margin, FY2022: 6.76%Net margin, FY2023: 1.80%Net margin, FY2024: -0.45%Net margin, FY2025: -4.04%Net margin, FY2026: -10.68%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 88.03%. Gross margin FY2023 85.73%. Gross margin FY2024 84.18%. Gross margin FY2025 80.73%. Gross margin FY2026 15.92%. Operating margin FY2022 12.44%. Operating margin FY2023 5.65%. Operating margin FY2024 2.59%. Operating margin FY2025 2.29%. Operating margin FY2026 0.92%. Net margin FY2022 6.76%. Net margin FY2023 1.80%. Net margin FY2024 -0.45%. Net margin FY2025 -4.04%. Net margin FY2026 -10.68%.

Income trends

Revenue

3.77B HKD-8.94%

Operating income

34.59M HKD-63.57%

Net income

−402.72M HKD-140.88%
Income trends across reported periods4.67B HKD2.83B HKD981.41M HKD−864.09M HKDRevenue, FY2022: 2.92B HKDRevenue, FY2023: 3.88B HKDRevenue, FY2024: 4.21B HKDRevenue, FY2025: 4.14B HKDRevenue, FY2026: 3.77B HKDOperating income, FY2022: 363.07M HKDOperating income, FY2023: 218.94M HKDOperating income, FY2024: 109.04M HKDOperating income, FY2025: 94.94M HKDOperating income, FY2026: 34.59M HKDNet income, FY2022: 197.5M HKDNet income, FY2023: 69.65M HKDNet income, FY2024: −18.95M HKDNet income, FY2025: −167.19M HKDNet income, FY2026: −402.72M HKDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 2.92B HKD. Revenue FY2023 3.88B HKD. Revenue FY2024 4.21B HKD. Revenue FY2025 4.14B HKD. Revenue FY2026 3.77B HKD. Operating income FY2022 363.07M HKD. Operating income FY2023 218.94M HKD. Operating income FY2024 109.04M HKD. Operating income FY2025 94.94M HKD. Operating income FY2026 34.59M HKD. Net income FY2022 197.5M HKD. Net income FY2023 69.65M HKD. Net income FY2024 −18.95M HKD. Net income FY2025 −167.19M HKD. Net income FY2026 −402.72M HKD.
Metric (HKD)FY2026FY2025FY2024FY2023FY2022
Revenue3.77B HKD4.14B HKD4.21B HKD3.88B HKD2.92B HKD
Cost of goods sold3.17B HKD797.95M HKD666.13M HKD552.95M HKD349.6M HKD
Gross profit600.33M HKD3.34B HKD3.54B HKD3.32B HKD2.57B HKD
Selling, general, and administrative—432.37M HKD426.37M HKD405.36M HKD302.02M HKD
Operating expenses565.75M HKD3.25B HKD3.36B HKD3.08B HKD2.18B HKD
Interest income16.02M HKD17.4M HKD15.57M HKD4.53M HKD1.36M HKD
Interest expense71.67M HKD89.44M HKD100.84M HKD63.64M HKD48.91M HKD
Depreciation and amortization512.24M HKD630.98M HKD625.55M HKD586.74M HKD432.37M HKD
Operating income34.59M HKD94.94M HKD109.04M HKD218.94M HKD363.07M HKD
Net income−402.72M HKD−167.19M HKD−18.95M HKD69.65M HKD197.5M HKD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
33%
1 beat, 2 misses, 0 met estimates
Average EPS surprise
-18.57%
3 comparable reports
Latest EPS result
-0.33

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.11-0.05-0.21-0.37Q4 '22MissQ2 '23No estimateQ4 '23No estimateQ2 '24No estimateQ4 '24No estimateQ2 '25No estimateQ3 '25No estimateQ2 '26No estimate
Q4 2022, reported Nov 24, 2022: actual 0.068, estimate 0.072, surprise -6.00%, Miss. Q2 2023, reported Jun 23, 2023: actual -0.001, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 30, 2023: actual 0.006, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 28, 2024: actual -0.022, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 28, 2024: actual 0.012, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 19, 2025: actual -0.15, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual -0.009, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 29, 2026: actual -0.33, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.21B2.06B1.91B1.75BQ2 '23BeatQ4 '23BeatQ2 '24BeatQ4 '24No estimateQ2 '25BeatQ3 '25No estimateQ2 '26No estimateQ4 '26Estimate
Q2 2023, reported Jun 23, 2023: actual 1.98B HKD, estimate 1.93B HKD, surprise +2.91%, Beat. Q4 2023, reported Nov 30, 2023: actual 2.12B HKD, estimate 2.08B HKD, surprise +1.97%, Beat. Q2 2024, reported Jun 28, 2024: actual 2.09B HKD, estimate 2.08B HKD, surprise +0.45%, Beat. Q4 2024, reported Nov 28, 2024: actual 2.06B HKD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 19, 2025: actual 2.08B HKD, estimate 2.08B HKD, surprise +0.11%, Beat. Q3 2025, reported Sep 30, 2025: actual 1.93B HKD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 29, 2026: actual 1.84B HKD, estimate —, surprise —, Comparison unavailable. Q4 2026, reported Nov 26, 2026: actual —, estimate 1.85B HKD, surprise —, Comparison unavailable.

2138.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

ETFs holding 2138.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis International Equity ETF logoAvantis International Equity ETFAVDE
Market value
2.53K
Weight
—
AUM
19.1B USD
Expense ratio
0.23%
Price / 1D
$94.26+0.87%
Avantis Responsible International Equity ETF logoAvantis Responsible International Equity ETFAVSD
Market value
151.75
Weight
—
AUM
369.1M USD
Expense ratio
0.23%
Price / 1D
$82.994+0.86%
Avantis International Small Cap Equity ETF logoAvantis International Small Cap Equity ETFAVDS
Market value
50.58
Weight
—
AUM
340.61M USD
Expense ratio
0.30%
Price / 1D
$80.49+0.93%

Continue in GoAI

Research 2138.HK

research.disclaimer